Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors

Inclusion Criteria: * Subjects must be ≥ 18 years of age. * Subjects must have histologically documented solid tumors (including lymphoma and multiple myeloma). * Specific criteria for individual tumor types are as follows: 1. Participants with gliomas are eligible at any stage of disease 2. Participants with pancreatic carcinoma are eligible at any stage of disease 3. Participants with rare tumors (i.e. cancer started in an unusual place in the body, it is unusual type and requires special treatment) are eligible at stages II-IV. 4. Participants with other tumor types must have recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer. * Must have an adequate formalin-fixed paraffin-embedded tumor specimen for genomic sequencing.